Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer's disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18219484.
- Also identified by DOI 10.1007/s00259-007-0710-0 and PMC identifier 2755760.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Molecular imaging aims towards the non-invasive characterization of disease-specific molecular alterations in the living organism in vivo. In that, molecular imaging opens a new dimension in our understanding of disease pathogenesis, as it allows the non-invasive determination of the dynamics of changes on the molecular level. IMAGING OF AD CHARACTERISTIC CHANGES BY microPET: The imaging technology being employed includes magnetic resonance imaging (MRI) and nuclear imaging as well as optical-based imaging technologies. These imaging modalities are employed together or alone for disease phenotyping, development of imaging-guided therapeutic strategies and in basic and translational research. In this study, we review recent investigations employing positron emission tomography and MRI for phenotyping mouse models of Alzheimer's disease by imaging. We demonstrate that imaging has an important role in the characterization of mouse models of neurodegenerative diseases.
Medical subject headings
- Alzheimer Disease
- Disease Models, Animal
- Molecular Probe Techniques
- Norepinephrine
- Plaque, Amyloid
- Positron-Emission Tomography